Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABBV-368 + tilsotolimod
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
ABBV-368 + tilsotolimod is an investigational combination therapy comprising **ABBV-368**, a fully human agonistic monoclonal antibody targeting OX40 (tumor necrosis factor receptor superfamily member 4, TNFRSF4), and **tilsotolimod** (IMO-2125), a synthetic Toll-like receptor 9 (TLR9) agonist oligodeoxynucleotide. ABBV-368 is designed to activate OX40 on T cells, thereby enhancing T-cell proliferation and survival, and potentially boosting adaptive anti-tumor immune responses. Tilsotolimod activates TLR9 in dendritic cells and other antigen-presenting cells, leading to type I interferon production, dendritic cell maturation, and increased antigen presentation. When used together, the combination is intended to enhance both innate and adaptive immune responses against tumors, particularly in solid malignancies such as advanced melanoma. Preclinical and early clinical data suggest this combination may reprogram the tumor microenvironment and promote durable anti-tumor activity.
- Other names
- ABBV-368 + IMO-2125
02
Targets
CD28 (Cluster of Differentiation 28)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on ABBV-368 + tilsotolimod.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABBV-368 + tilsotolimod.